Crizotinib: A targeted therapy in advanced ALK-positive non-small cell lung cancer

被引：0

作者：

Toffart, A. -C. ^{[1
,2
]}

Sakhri, L. ^{[1
,2
]}

Moro-Sibilot, D. ^{[1
,2
]}

机构：

[1] Ctr Hosp Univ A Michallon, UM Oncol Thorac, F-38043 Grenoble 9, France

[2] Univ Grenoble 1, Inst A Bonniot, INSERM, U823, Grenoble, France

来源：

REVUE DE PNEUMOLOGIE CLINIQUE | 2013年 / 69卷 / 02期

关键词：

EML4-ALK; Lung cancer; Crizotinib; Targeted therapy; Never smoker; Adenocarcinoma; EML4-ALK FUSION GENE; KINASE INHIBITOR; RESISTANCE; REARRANGEMENT; MUTATIONS; EFFICACY; MET; NPM;

D O I：

10.1016/j.pneumo.2012.11.010

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

Crizotinib is a small orally-administered ALK inhibitor for patients with non-small cell lung cancer with EML4-ALK rearrangement (echinoderm microtubule-associated protein-like 4 and anaplastic lymphoma kinase). This fusion gene is detected with a break apart fluorescence in situ hybridization (FISH) assay. Phase I to III trials have shown an interesting disease control rate and acceptable tolerability. Crizotinib is available in France under temporary use authorization. New potentially effective therapeutics in ALK-positive NSCLC are being developed. (C) 2013 Elsevier Masson SAS. All rights reserved.

引用

页码：111 / 116

页数：6

共 50 条

[1] Crizotinib as first line therapy for advanced ALK-positive non-small cell lung cancers
Chuang, Jody C.
Neal, Joel W.
TRANSLATIONAL LUNG CANCER RESEARCH, 2015, 4 (05) : 639 - 641
[2] Clinical observation of crizotinib in the treatment of ALK-positive advanced non-small cell lung cancer
Deng, Huiyan
Li, Bin
Li, Lina
Peng, Jingcui
Lv, Tongshuai
Liu, Yueping
Ding, Cuimin
PATHOLOGY RESEARCH AND PRACTICE, 2019, 215 (12)
[3] Crizotinib versus Chemotherapy in Asian Patients with ALK-Positive Advanced Non-small Cell Lung Cancer
Nishio, Makoto
Kim, Dong-Wan
Wu, Yi-Long
Nakagawa, Kazuhiko
Solomon, Benjamin J.
Shaw, Alice T.
Hashigaki, Satoshi
Ohki, Emiko
Usari, Tiziana
Paolini, Jolanda
Polli, Anna
Wilner, Keith D.
Mok, Tony
CANCER RESEARCH AND TREATMENT, 2018, 50 (03): : 691 - 700
[4] Heterogeneous responses and resistant mechanisms to crizotinib in ALK-positive advanced non-small cell lung cancer
Kang, Jin
Chen, Hua-Jun
Zhang, Xu-Chao
Su, Jian
Zhou, Qing
Tu, Hai-Yan
Wang, Zhen
Wang, Bin-Chao
Zhong, Wen-Zhao
Yang, Xue-Ning
Chen, Zhi-Hong
Ding, Yan
Wu, Xue
Wang, Mei
Fu, Jian-Gang
Yang, Zhenfan
Zhang, Xian
Shao, Yang W.
Wu, Yi-Long
Yang, Jin-Ji
THORACIC CANCER, 2018, 9 (09) : 1093 - 1103
[5] BUDGET IMPACT OF CRIZOTINIB FOR ALK-POSITIVE ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IN COLOMBIA
Rosado-Buzzo, A.
Garcia-Mollinedo, L.
Luna-Casas, G.
Mould-Quevedo, J. F.
Gutierrez-Ardila, M., V
Vargas Zea, N.
VALUE IN HEALTH, 2013, 16 (03) : A132 - A132
[6] Crizotinib: A New Treatment Option for ALK-Positive Non-Small Cell Lung Cancer
O'Bryant, Cindy L.
Wenger, Sarah D.
Kim, Miryoung
Thompson, Lisa A.
ANNALS OF PHARMACOTHERAPY, 2013, 47 (02) : 189 - 197
[7] Efficacy and tolerability of crizotinib in the treatment of ALK-positive, advanced non-small cell lung cancer in Chinese patients
Shaohua Cui
Yizhuo Zhao
Aiqin Gu
Xiaoxiao Ge
Yanyan Song
Wei Zhang
Yuqing Lou
Lili Dong
Baohui Han
Liyan Jiang
Medical Oncology, 2015, 32
[8] ESTIMATING THE BUDGET IMPACT OF CRIZOTINIB FOR ALK-POSITIVE ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IN ARGENTINA
Wang, B.
Furnback, W.
Xuan, J.
VALUE IN HEALTH, 2014, 17 (03) : A74 - A74
[9] CLINICAL EXPERIENCE WITH CRIZOTINIB IN SPECIAL POPULATIONS WITH ADVANCED ALK-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC)
Ahn, M-J
Crino, L.
Solomon, Ben
Zhou, Caicun
Ou, Sai-hong I.
Selaru, P.
Cohen, D. P.
Bartlett, C. H.
Kim, Dong-wan
JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (11) : S490 - S491
[10] Renal effects of crizotinib in patients (pts) with ALK-positive (+) advanced non-small cell lung cancer (NSCLC)
Kim, E.
Usari, T.
Polli, A.
Lewis, I.
Wilner, K.
JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (04) : S134 - S134

← 1 2 3 4 5 →